Innovations - University of Maryland Greenebaum Cancer Center

SUMMER
2005
INNOVATIONS
IN THIS ISSUE
Outpatient Services Unite
Welcome from the Director
Patient Navigator
UMGCC Researcher Wins Award
Clinical Trial Update
Research & Grants
New Web Features
Patient Success Story
New Faculty
News & Accolades
Improving Physician Access
OUTPATIENT SERVICES COME
TOGETHER UNDER ONE ROOF OF
THE NEW STOLER PAVILION
The University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC)
opened its state-of-the-art ambulatory facility in June, consolidating outpatient oncology
services in one location and providing a highly visible “center” for the cancer center.
The 25,000-square-foot outpatient center, called the Roslyn and Leonard Stoler Ambulatory
Pavilion, is located on the first floor of the University of Maryland Medical Center, with its
entrance off the main lobby.
“The new outpatient pavilion is very welcoming and patient-friendly. It enhances our outpatient
facilities and gives the University of Maryland Marlene and Stewart Greenbaum Cancer Center a
significant presence on the first floor of the medical center,” says Kevin J. Cullen, M.D., UMGCC
Director and Professor of Medicine at the University of Maryland School of Medicine. “It increases
access to the cancer center’s comprehensive, multidisciplinary approach to treatment.”
“We are very grateful to the Stolers for their magnificent gift,” he adds.
The new facility, part of a major expansion planned for the cancer center, is named for
Leonard Stoler, a Baltimore-area businessman who owns 13 auto dealerships, and his wife,
Roslyn. The couple donated $5 million last year for the new outpatient center.
To learn more about the advanced technology
and care provided at the University of Maryland
Marlene and Stewart Greenebaum Cancer Center,
please call 1-800-373-4111 or visit...
www.umgcc.org
“There are very few things that you can do that truly make a difference in a person’s life. In
doing something for cancer patients, I think you are really making a difference,” Mr. Stoler,
the founder and president of Len Stoler Automotive, said in making the gift.
Continued on page 2

WELCOME FROM
THE DIRECTOR
At the University of Maryland Marlene and Stewart Greenebaum
Cancer Center, we’re changing the face of cancer. We are excited to
share some of these changes with you in this issue of Innovations,
which has received a facelift of its own.
This June, one of our most visible changes took place as we opened
the Roslyn and Leonard Stoler Ambulatory Pavilion. This 25,000
square foot facility located just inside the main entrance of the
University of Maryland Medical Center, gives a new look to the
excellent patient care we provide at UMGCC. With patient comfort
and ease of access at the forefront of our architectural plans, the
Stoler Pavilion is a centralized location for outpatient services.
Another visible change to the cancer center is our website. A new
design and a new domain name – UMGCC.org – make the plethora
of information for patients and physicians easier to find and is more
complete than ever before.
Less visible but unquestionably important examples of how we are
changing cancer care lay in the developments and advances in our
clinical and research programs. For example, a new trial involving
vaccine treatment for men with rising PSA levels following diagnosis
and treatment of prostate cancer has begun, as has a trial evaluating
combination therapy with Velcade for the treatment of lung cancer.
New telemedicine capabilities make access to our expertise here in
Baltimore and our other resources, such as clinical trials, easier for
community oncologists, as you will read in the patient success story.
I am very pleased to inform you that Angela Brodie, Ph.D., professor
of pharmacology and experimental therapeutics, has been
awarded the very prestigious General Motors Kettering Prize for
cancer research for her work in the development of aromatase
inhibitors. Her research has led to a new class of drugs that help
prevent women who have completed breast cancer treatment from
relapsing. Dr. Brodie is one of our leading investigators in our newly
reorganized hormone responsive cancers research program, where
investigators are focused on breast and prostate cancer.
For more information about any of the content included in this
newsletter, or to learn more about UMGCC, please call us at
1-800-373-4111 or visit www.umgcc.org.
Director, University of Maryland Marlene and Stewart Greenebaum
Cancer Center and Professor of Medicine, University of Maryland
School of Medicine
OUTPATIENT SERVICES COME TOGETHER
UNDER ONE ROOF OF THE NEW STOLER
PAVILION Continued from page 1.
Barry Meisenberg, M.D., UMGCC Deputy Director of Clinical
Affairs and professor of medicine at the University of Maryland
School of Medicine, says, “The Stoler Pavilion gives our patients and
staff a true sense of the University of Maryland Marlene and Stewart
Greenebaum Cancer Center as a ‘center’ for cancer care. It brings
together outpatient services that were located in several different
areas.”
The Stoler Pavilion houses the medical oncology and the bone marrow/
stem cell transplantation exam rooms, and clinic areas for multidisciplinary
programs. It also provides support services, such as social work and
nutrition counseling, as well as patient education space.
The Stoler Pavilion has 28 exam rooms, an infusion therapy center
featuring flat screen monitors and internet access in its 22 treatment
bays and three treatment rooms, a phlebotomy room, conference
rooms with telemedicine capabilities, meeting rooms and a pharmacy
specific to the infusion center. Elevators link the new pavilion
directly to the cancer center’s inpatient units and offices on the
eighth and ninth floors.
“The clinical area is designed around our multidisciplinary approach to
diagnosing and treating cancer patients,” says Mark Krasna, M.D.,
UMGCC Associate Director and professor of surgery. “The exam
rooms are clustered in pods with meeting rooms where our teams of
doctors can discuss the best treatment options for patients. New
patients will be able to see a surgeon, radiation oncologist and medical
oncologist without having to leave the pavilion. They will then
come back to the Stoler Pavilion for treatment and follow-up visits.”
“Having everything in one central location is a much more efficient way
of meeting the needs of our patients and their families,” says Mohan
Suntha, M.D., UMGCC Associate Director for Multidisciplinary
Programs and Outreach and associate professor of radiation oncology.
“It will be a comfortable place for patients as well as for the physicians,
nurses and other members of the cancer center staff.”
The Stoler Pavilion is a key part of a major expansion of the cancer
center’s clinical and research facilities. Additional inpatient beds are
being added to support the cancer center's growth. UMGCC is also
undertaking a major expansion of its research laboratory space.
For more information about the Roslyn and Leonard Stoler Pavilion,
please visit www.umgcc.org or call 1-800-373-4111.
2 | INNOVATIONS

Above: One new feaure of the Roslyn and Leonard Stoler Pavilion, depicted
above, is a patient navigator.
PATIENT NAVIGATOR
Everything in the Roslyn and Leonard Stoler Pavilion is new. The
carpet. The exam rooms. The registration desk. But one new
feature of the pavilion might not be so quickly recognized – the
Patient Navigator.
UMGCC has partnered with the American Cancer Society to provide
a patient navigator for patients who may need assistance in
reaching their appointment locations or accessing information or
other resources that will help them with their care.
“When patients learn they have been diagnosed with cancer, it can
often be overwhelming,” explains Kevin Cullen, M.D., director of the
cancer center. In many cases, patients do not have all the support
systems they will need as they start the diagnosis and treatment
process. “Issues such as transportation or not knowing how to organize
and coordinate the logistics around their care can lead to some
patients falling through the cracks,” he continues. The patient
navigator will team up with these patients and help them not only
learn what resources are available to them, but help them make use
of those resources.
The patient navigator will help patients connect with support services
such as nutrition and social work, arrange transportation and child
care, obtain financial assistance and access any additional resources that
will help them through their cancer treatments.
“The navigator will ensure patients are better able to adhere to their
treatment plan and help them benefit from all of the services available
through UMGCC and the American Cancer Society that they may
have otherwise not know about,” adds Dr. Cullen.
To obtain additional information about the Patient Navigator at
UMGCC, please call 1-800-373-4111 or visit www.umgcc.org.
UMGCC RESEARCHER
AWARDED PRESTIGIOUS
KETTERING PRIZE
Angela Brodie, Ph.D., has been named this
year's recipient of the Kettering Prize from
the General Motors Cancer Research
Awards (GMCRA). The Kettering Prize is
awarded for the most outstanding recent
contribution to the diagnosis or treatment
of cancer. Dr. Brodie is professor of pharmacology
and experimental therapeutics at the
University of Maryland School of Medicine
and a researcher at the University of
Maryland Marlene and Stewart Greenebaum Cancer Center in the
Hormone Responsive Cancers Program.
The award honors Dr. Brodie's pioneering work in the development
of aromatase inhibitors. This class of drugs, now in use worldwide,
represents perhaps the most important advance in the treatment of
breast cancer in the last two decades.
Formestane was the first selective aromatase inhibitor to be used clinically,
and at that time was the only new drug specifically designed
for the treatment of breast cancer in 10 years. It was released for
worldwide use in 1994. More recently, in 2003 letrozole was found
to be so effective in early breast cancer after five years of tamoxifen
that a recent clinical trial was stopped early so that patients who had
been taking the placebo could be given the new drug.
Today, many thousands of women worldwide now benefit from the
outstanding work of Dr. Brodie and her team.
The GMCRA awards include the Kettering Prize, the Mott Prize for
epidemiology and the Sloan Prize for basic science. Together, they are
among the most prestigious awards in all of science. Dr. Brodie joins
105 previous awardees, 12 of whom subsequently won the Nobel
Prize. She and the other laureates lectured at the GMCRA annual scientific
conference held at the NIH June 14-18. Most appropriately,
the topic of this year’s conference was breast cancer. She formally
received the award at a gala in Washington, DC, on June 15.
SUMMER 2005 | 3

CLINICAL TRIAL UPDATE
NEW VACCINE STUDY UNDERWAY FOR
MEN WITH RISING PSA LEVELS
The University of Maryland Marlene and Stewart Greenebaum
Cancer Center’s Genitourinary Oncology Program and the University
of Maryland Division of Urology have opened one of the nation’s first
clinical trials studying the effects of a prostate specific antigen (PSA)
vaccine on the immune system of men diagnosed with recurrent prostate
cancer. If the PSA vaccine boosts the T lymphocyte immune response
in this Phase II study, clinicians may have a treatment option to offer
patients who are at risk for developing metastatic prostate cancer.
To Richard Alexander, M.D., principal investigator of the study,
chief of the Baltimore Veterans Affairs Medical Center Urology
Service and associate professor at the University of Maryland School
of Medicine, the need for an effective treatment for men with
advanced prostate cancer is clear: “30,000 men die of prostate cancer
each year and they die of metastatic disease.” Many men with
Clinicians know that men with elevated PSA levels after surgery have
a higher rate of disease recurrence and death compared to those with
undetectable PSA levels. What they don’t know, however, is what
happens in the time that passes between surgery and identification of
metastatic disease. For an average of eight years, men with detectable
and rising PSA levels present with no other symptoms of disease and
are generally healthy. Clinicians see this window – during which there
are currently no treatment options – as the opportune time to use the
body as its own defense and mount an immunologic response to halt
progression of the remaining cancerous cells.
“It is now firmly established that cancerous tumors contain antigens
that can be specifically recognized by the immune system and this
recognition can be exploited as therapeutic,” introduces Dr.
Alexander. “We hope to stimulate the immune system to destroy
prostatic cancerous cells throughout the body before they develop
enough for us to identify metastatic disease,” he remarks.
“30,000 men die of prostate cancer each year
and they die of metastatic disease.”
prostate cancer are essentially cured when their localized disease is
treated, but effective therapy doesn’t exist to treat the cancer when it
advances. “The very patients who have prostate cancer that will most
likely shorten their lives and who need our help the most are the ones
for whom we can do the least,” he notes.
Men at risk for metastatic disease are identified by a rise in PSA levels
after surgery is performed. Usually, elevated levels of PSA are secreted
by a man’s prostatic epithelium when one of a few conditions of
prostate develop, most notably cancer. If the PSA levels do indeed
point to cancer and not a benign condition, the patient may choose
to undergo a radical prostatectomy. “Since PSA is specific for the
prostate gland, if the entire prostate gland is removed, then PSA
should fall to undetectable or female levels,” explains Nancy
Dawson, M.D., co-investigator for the study, director of the genitourinary
medical oncology program and professor of medicine.
“The presence of elevated PSA levels in a man after radical prostatectomy,
especially within one year of surgery, suggests that he has
prostatic epithelial cells, either benign or malignant, remaining
somewhere in his body,” she adds.
The PSA peptide, called PSA: 154-163(155L), will be administered
subcutaneously with adjuvant Montanide® ISA-51 on an outpatient
basis every other week for four doses, then every four weeks for three
doses. Patients eligible for the trial must have undergone radical
prostatectomy at least three months prior to enrollment, have
detectable and rising PSA levels (> 0.6 ng/ml) over three months, have
received no radiation or hormonal therapy and have a life expectancy
of greater than one year.
Effects of the vaccine will be gauged by the increase in peptide-specific
T cells in peripheral blood collected at the baseline and one week
after the last dose of the vaccine. A positive response is considered
either a five-fold increase in specific T cells in patients who had significant
baseline numbers or the presence of cells in patients who did
not. A decline in serum PSA of at least 50% compared to baseline
will also be considered a positive response.
To learn more about this trial, refer a patient you think may be a candidate
or find out what other trials are currently underway at the University
of Maryland Marlene and Stewart Greenebaum Cancer Center, please
call 1-800-373-4111 or visit www.umgcc.org.
4 | INNOVATIONS

EVALUATING NOVEL COMBINATION THERAPY WITH
VELCADE FOR STAGE III LUNG CANCER PATIENTS
Oncologists at the University of Maryland Marlene and Stewart
Greenebaum Cancer Center have begun enrolling patients in a Phase
I clinical trial evaluating treatment of Stage III non-small cell lung
cancer with Velcade in combination with standard chemotherapy and
radiation therapy.
Velcade, a proteasome inhibitor, was approved by the FDA in 2003
for the treatment of multiple myeloma. The drug blocks proteasomes,
which play a roll in the growth and survival of cells. When the
enzymes are blocked, cancer cells die.
“Velcade has been shown to boost the effectiveness of radiation in laboratory
studies, but it has never been combined with radiation to treat
patients with non-small cell lung cancer. We were the first institution
to test this new combination therapy,” notes Martin J. Edelman,
M.D., director of thoracic medical oncology and the study’s principal
investigator at UMGCC. Dr. Edelman is an associate professor of
medicine at the University of Maryland School of Medicine.
Patients enrolled in the study will receive paclitaxal and carboplatin in
addition to radiation therapy and Velcade for six weeks. After this
initial treatment, surgery will be considered for patients whose tumors
are small enough. Standard chemotherapy will be offered to nonsurgical
candidates and to patients following surgery.
“We know that combining chemotherapy and radiation can aid some
people with lung cancer and the combination clearly improves
survival rates compared with radiation or surgery alone.
Chemotherapy and radiation, followed by surgery, may be an even
better treatment option for certain patients,” Dr. Edelman explains.
“We want to find out if a newer agent, such as Velcade, can enhance the
value of radiation or chemotherapy in treating this type of lung cancer.”
Co-investigators of this study include Mohan Suntharalingam,
M.D., vice chairman and associate professor of radiation oncology at
the University of Maryland School of Medicine, and King F. Kwong,
M.D., a thoracic surgeon and assistant professor of surgery.
“This study builds on the University of Maryland’s expertise in the
multi-modality treatment of non-small cell lung cancer,” Dr.
Edelman says. It is one of more than a dozen current clinical trials
ongoing for patients with lung cancer.
For more information, call 1-800-373-4111 or visit www.umgcc.org.
Left: A Cancer
Center researcher
works in his lab.
RESEARCH & GRANTS
RESEARCH INITIATIVES COMBINE TO FORM HORMONE
RESPONSIVE CANCERS PROGRAM
The University of Maryland Marlene and Stewart Greenebaum Cancer
Center’s Breast Cancer and Prostate Cancer research programs recently
merged to become the Hormone Responsive Cancers (HRC) Program.
Combining breast and prostate research into one program takes full
advantage of the fact that the hormone response mechanism of estrogen
and testosterone are very similar in many respects. This new combined
program ties outstanding investigators in breast and prostate cancer
together (including Dr. Angela Brodie, featured on page 3), enabling
easier sharing of discoveries and advances made in the laboratory and
quicker development of innovative approaches to diagnosis, treatment
and prevention of malignancies of the reproductive system.
The Hormone Responsive Cancers Program is home to many projects
that are directed toward the identification of novel or overexpressed
molecules that can serve as new biomarkers, aid in diagnosis,
improve existing treatments and function as targets for novel therapies.
The HRC program has five major focus areas including hormone and
peptide growth factors, biology of tumor angiogenesis, drug resistance
and apoptosis, immunotherapy and tumor invasion and metastasis.
NEW WEB FEATURES
The University of Maryland Marlene and Stewart Greenebaum
Cancer Center website has a new look – and a new name. With
great information for cancer patients and practitioners alike,
www.umgcc.org is a site to be bookmarked.
New navigation and an area dedicated exclusively to oncologists are
two new components to www.umgcc.org. Patient success stories, up
to date information on clinical trials and email links to some of our
physicians are all features on the website.
Please visit us at www.umgcc.org.
SUMMER 2005 | 5

PATIENT SUCCESS STORY
TELEMEDICINE LINKS CANCER EXPERTS
IN COORDINATING PATIENT'S CARE
When Leonard (Lenny) Fishbein received his diagnosis of advanced
lung cancer three years ago, his odds of survival were not good. At
age 72, he had been a smoker for over 50 years. Despite regular
chest X-rays, his lung cancer had gone undetected, and was now
stage IV, meaning that it had spread to another part of his body. In
fact, neurological symptoms, specifically tremors on the right side
of his body, were what originally sent him to the doctor.
“My wife noticed me shaking one day at the kitchen table, and she
insisted I go to a doctor after I admitted I had two other episodes
previously,” says the Rockville, Maryland resident. Tests revealed
several lesions on his brain and a small tumor on his lung.
Fishbein’s son, Dr. David M. Fishbein, a gastroenterologist in
Baltimore, recommended a colleague, Mark Krasna, M.D., professor
of surgery at UMGCC. It was quickly determined that Fishbein’s
brain lesions were the result of metastasized lung cancer. His plan of
care would be two-pronged: first, get rid of the lesions on his brain,
and then address the lung cancer.
“My wife noticed me shaking
one day at the kitchen table,
and she insisted I go to a
doctor after I admitted I had
two other episodes previously,”
Fishbein’s oncologist, Dr. J. Garrett Riley, referred him to Luther
Ampey, M.D., medical director of the Helen P. Denit Center for
Radiation Therapy at Montgomery General Hospital and assistant
professor of radiation oncology at the University of Maryland
School of Medicine. Montgomery General is one of three affiliated
community radiation oncology centers where University of
Maryland physicians and staff provide patient care and are linked
to the oncology specialists at the UMGCC’s downtown Baltimore
campus through a telemedicine link.
Above Left: Lenny Fishbein and his granddaughter.
Above Right: Drs. Regine and Chin discuss a course of treatment.
Using state-of-the-art telemedicine technology, Dr. Ampey, sitting
in his conference room at Montgomery General, was able to present
Fishbein’s case to his colleagues at UMGCC in Baltimore.
“Videoconferencing allows us to collaborate on how to provide the
best treatment possible. The more minds that you can put to a case,
the more angles can be discussed and pursued,” Dr. Ampey said. “It
makes it a lot easier to coordinate a patient’s care.”
Treatment began with a course of whole brain radiation followed
by lung radiation over several weeks at Montgomery General’s radiation
oncology center to shrink the lesions. This was followed by
several months of aggressive chemotherapy.
Next was the Gamma Knife Center at UMGCC, where Fishbein
met with Lawrence Chin, M.D., associate professor of neurosurgery
and medical director of the Gamma Knife Center. He underwent
gamma knife radiosurgery, a procedure that uses high-dose ionizing
radiation to attack the tumor without traditional surgery. Fishbein
was able to go home the next day.
With the brain lesions taken care of, he was ready for the treatment team
to address his underlying problem, the primary cancer in his lung. Dr.
Krasna performed minimally-invasive surgery to remove the lesion from
Fishbein’s lung. Says Fishbein, “It was a breeze. I didn’t feel a thing.”
Looking back, Fishbein credits his doctor-son for his good advice, his
local oncologist for his coordination with all the UMGCC doctors,
his daughter-in-law for swiftly setting his appointments and tests,
and his wife for all of her support.
Three years later, he appears to have beaten the odds, thanks to cutting-edge
technology for cancer treatment, care by a skilled team of
specialists, and the technology that linked them all together. Checkups
continue to show him to be disease-free and he’s feeling great. An athletic
lifestyle — he played and coached baseball all his life — and his
comedian sense of humor probably played a key role in his recovery.
While he can no longer swing a bat or round third base like he used
to, surviving cancer has been the biggest “win” of his life.
6 | INNOVATIONS

NEW FACULTY
SAUL YANOVICH, M.D., HAS JOINED
UMGCC AS CLINICAL DIRECTOR OF
THE BLOOD AND MARROW
TRANSPLANTATION PROGRAM
Saul Yanovich, M.D., a nationally recognized blood and marrow transplant
physician and researcher, has joined the University of Maryland
Marlene and Stewart Greenebaum Cancer Center as clinical director
of the Blood and Marrow Transplantation (BMT) Program and the
University of Maryland School of Medicine as a faculty member.
Most recently the medical director of Georgetown University’s
Lombardi Cancer Center’s Bone Marrow Transplant Program
in Washington, D.C., Dr. Yanovich plans to build on the
exceptional patient care provided by its well-established BMT
program and expand the innovative therapies offered through
clinical trials at UMGCC.
Dr. Yanovich is well published in his field and is recognized nationally
for his research and clinical practice in blood and marrow
transplantation. Prior to his appointment at Georgetown, Dr.
Yanovich directed the Bone Marrow Transplantation Unit at the
Medical College of Virginia in Richmond.
A graduate of Javeriana University School of Medicine in Bogota,
Colombia, Dr. Yanovich completed his medical residency and
a hematology fellowship at the University of Miami. He also
completed a research oncology fellowship at the Dana Farber
Cancer Center Institute of Harvard Medical School in Boston.
To contact Dr. Yanovich, please call 1-800-373-4111 or visit our
website at www.umgcc.org.
NEWS &
ACCOLADES
UMGCC MAJOR SUPPORTER OF
SUMMER MYELOMA SEMINAR
The International Myeloma Foundation is
hosting a Patient/Family Seminar in Baltimore,
August 19-20, 2005. UMGCC is a proud
supporter of this event, designed to empower
patients and provide current, extensive
information to patients diagnosed with
myeloma and their families. For more information
about this seminar, please visit
www.myeloma.org or call 1-800-373-4111.
BMT TEAM HONORED
The Mildred Mindell Cancer Foundation honored
the University of Maryland Marlene and
Stewart Greenebaum Cancer Center's Blood
and Marrow Transplant (BMT) Team at an
April 3 fundraising event to benefit the transplant
unit. Recognized for their outstanding
efforts in providing cancer care to patients were
Ashraf Z. Badros, M.D., Barry R. Meisenberg,
M.D., and Aaron P. Rapoport, M.D.
DAILY RECORD RECOGNIZES
HEALTH CARE HEROES
The Baltimore City Cancer Program was
named the 2005 community outreach winner
of the Daily Record’s Health Care Heroes
Award. The program has provided education
and screenings for more than 8,000 women
and identified cancer in 38 since 2001.
Kathy Ruehl, R.N., O.C.N., C.H.T.C., senior
nurse coordinator, was recognized as a Health
Care Hero finalist for her exceptional contributions
to the UMGCC Marrow/Stem Cell
Transplant Program.
FACULTY PRESENTATIONS
AND GRANT AWARDS
Doug Ross, M.D., Ph.D., head of developmental
therapeutics at UMGCC, was a
keynote speaker at the 2004 Japanese Society
for the Study of Xenobiotics in Kanazawa
Japan. He presented “The Role of the ABC
transporter breast cancer resistance protein
(BCRP, ABCG2) in drug disposition” at the
meeting held November 17-19.
Peter Gutierrez, Ph.D., presented information
on his work in proteomics at the first
annual US Human Proteome Organization
Symposium held in Washington, DC
March 13-16, 2005.
Stephen J Meltzer, M.D., director of the
Aerodigestive Oncology Program at UMGCC,
was awarded a T-32 GI Training Grant of
$1.6 million over five years.
Sanford A Stass, M.D., of the UMGCC
Experimental Therapeutics Program recently
accepted a five-year $1.5 million grant from the
Biomarkers Reference Laboratories, a section of
the NCI Early Detection Research Network.
Bruce Line, M.D., and the American Russian
Cancer Alliance received a one-year $175,000
grant to further their work transforming
radioactive isotopes from Russian nuclear
stockpiles to cutting-edge cancer therapies.
PATIENT VIDEO SILVER WINNER
Congratulations to the Department of
Radiation Oncology whose video, A Patient
Guide to Radiation Therapy, was honored with a
silver Aster Award, a national medical marketing
awards program. For a copy of this video on
tape or CD, please call 1-800-373-4111.
SUMMER 2005 | 7

IMPROVING PHYSICIAN ACCESS
SENIOR ATTENDING ON CALL 24/7 TO TAKE YOUR CALL
We want to make access to the University of Maryland Marlene and
Stewart Greenebaum Cancer Center as easy as possible. That’s why
we’ve recently enhanced the University Physicians Consultation and
Referral Service for UMGCC.
Our consultation and referral line has always provided high quality
service for transfers, referrals and consultation requests around the
clock. Now we have added a new dimension to this service for physicians
calling UMGCC to ensure you have immediate access to a senior
oncology attending physician – 24 hours-a-day, 7 days-a week.
When you call 1-800-373-4111, you are transferred to the UMGCC
program or attending you request. If you don’t know with whom you
want to speak, or if the attending on the service you are trying to
contact cannot speak to you immediately, our enhanced service can
help complete your call. You’ll be connected with a senior UMGCC
attending physician who is on-call specifically for this purpose.
Questions, comments or requests for copies of Innovations Contact
Angela Colella at 410-328-6338 or acolella@umm.edu
Innovations is an information service of the University of Maryland
Marlene and Stewart Greenbaum Cancer Center.
ADVISORY BOARD
Kevin J. Cullen, M.D.
Professor and Director, UMGCC
Barry Meisenberg, M.D.
Professor and Deputy Director of
Clinical Affairs, UMGCC
Mark J. Krasna, M.D.
Professor and Associate
Director, UMGCC
Mohan Suntha, M.D.
Associate Professor and Associate
Director for Multidisciplinary
Programs and Outreach, UMGCC
To learn more about the advanced technology
and care provided at the University of Maryland
Marlene and Stewart Greenebaum Cancer Center,
please call 1-800-373-4111 or visit...
www.umgcc.org
22 South Greene Street
Baltimore, Maryland 21201
Non-Profit Org.
U.S. Postage
PAID
Permit #2573
Baltimore, MD
UMGCC Programs
Blood and Marrow Transplant
Bone and Soft Tissue Oncology
Brain Tumor Center
Breast Evaluation and Treatment
Gastrointestinal Oncology
Genitourinary Oncology
Gynecological Oncology
Head and Neck Oncology
Hematologic Malignancies
Myeloma
Thoracic Oncology